Reduction of cardiac adipose tissue volume with short-term empagliflozin treatment in patients with type 2 diabetes: a sub-study from the SIMPLE randomized clinical trial.
Niels H Brandt-JacobsenMikkel JürgensPhilip HasbakPeter GaedeEllen BurgessJon J RasmussenCamillla Fuchs AndersenJulie L FormanJens FaberCatherine M ViscoliFinn GustafssonMorten SchouCaroline KistorpPublished in: Diabetes, obesity & metabolism (2022)
Empagliflozin provides an early reduction of CAT, however, no association was observed with concurrent changes in cardiac volumetrics. This article is protected by copyright. All rights reserved.